US President Donald Trump 's announcement of a 100% tariff on imported "branded and patented pharmaceutical products" has rattled the global pharma industry, though Indian generic drug makers are largely expected to remain unaffected for now. Trump, in a post on Truth Social on Thursday, stated: "Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. ‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. " The announcement sent shockwaves across Indian pharma stocks, raising concerns that the scope of the tariffs could late

See Full Page